Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole

Area of Science:

• Mycology
• Pharmacology
• Infectious Diseases

Background:

• Isavuconazole is an extended-spectrum triazole antifungal approved for invasive aspergillosis and mucormycosis.
• It exhibits broad-spectrum activity against yeasts, dimorphic fungi, and molds.
• Compared to voriconazole, isavuconazole presents with fewer toxicities and drug-drug interactions.

Purpose of the Study:

• To review the pharmacokinetics and pharmacodynamics of isavuconazole.
• To discuss the expanding clinical applications of isavuconazole.

Main Methods:

• Literature review of existing studies on isavuconazole.
• Analysis of pharmacokinetic and pharmacodynamic data.
• Exploration of clinical trial outcomes and post-marketing data.

Main Results:

• Isavuconazole demonstrates predictable pharmacokinetics in adult populations.
• The agent is available in both oral and intravenous formulations, with the latter being β-cyclodextrin-free.
• Fewer toxicities and drug-drug interactions are associated with isavuconazole compared to voriconazole.

Conclusions:

• Isavuconazole represents a significant advancement in antifungal therapy.
• Its favorable safety and pharmacokinetic profile supports its expanding role in treating invasive fungal infections.
• Further research into its applications and long-term outcomes is warranted.